Several brokerages have updated their recommendations and price targets on shares of Alumis (NASDAQ: ALMS) in the last few weeks:
- 11/16/2026 – Alumis had its price target lowered by Oppenheimer to $28.00. They now have an “outperform” rating on the stock.
- 11/13/2026 – Alumis was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
- 11/13/2026 – Alumis had its price target lowered by Wells Fargo & Company from $25.00 to $18.00. They now have an “overweight” rating on the stock.
- 11/13/2026 – Alumis had its price target lowered by HC Wainwright from $15.00 to $9.00. They now have a “buy” rating on the stock.
- 10/27/2026 – Alumis was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
- 10/5/2026 – Alumis had its “buy” rating reaffirmed by Benchmark.
- 10/5/2026 – Alumis had its “buy” rating reaffirmed by HC Wainwright.
- 10/2/2026 – Alumis had its “sell (d-)” rating reaffirmed by Weiss Ratings.
Alumis Price Performance
Alumis stock opened at $5.14 on Tuesday. The stock’s fifty day moving average price is $7.12 and its two-hundred day moving average price is $20.35. Alumis Inc. has a one year low of $5.00 and a one year high of $31.35. The firm has a market cap of $665.27 million, a PE ratio of -1.46 and a beta of -0.28.
Alumis (NASDAQ:ALMS – Get Free Report) last released its earnings results on Thursday, November 12th. The company reported ($0.73) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.03. The firm had revenue of $1.91 million during the quarter, compared to the consensus estimate of $1.90 million. Alumis had a negative return on equity of 86.62% and a negative net margin of 5,844.54%. Sell-side analysts expect that Alumis Inc. will post -2.95 earnings per share for the current fiscal year.
Insider Activity at Alumis
Alumis is a clinical-stage biopharmaceutical company developing medicines for autoimmune and inflammatory diseases. The company uses data and computational tools to support the discovery and development of targeted treatments. Its lead investigational program, ESK-001, is an oral, selective TYK2 inhibitor being studied for conditions including plaque psoriasis and systemic lupus erythematosus. Alumis is also advancing other drug candidates for immune-mediated diseases. These medicines remain in clinical development and are not approved for commercial use.
Read More
- Five stocks we like better than Alumis
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Alumis Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alumis Inc and related companies with MarketBeat.com's FREE daily email newsletter.
